4-(6-chloro-5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: 4-(6-chloro-5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
• 英文别名: 4-(6-chloro-5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane；6-Chloro-2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-methyl-[1,3]oxazolo[4,5-b]pyridine
• 化学式: C₁₄H₁₇ClN₄O
• 分子量: 292.768
• InChiKey: PKPRDSSAMMLSLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  45.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(6-chloro-5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 4-(6-chloro-5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane hydrochloride
  参考文献：
  名称：

  WO2006/51407

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(5-Methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane 在 N-氯代丁二酰亚胺 作用下， 以 氯仿 为溶剂， 反应 0.17h， 以70%的产率得到4-(6-chloro-5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075

文献信息

• Azabenzoxazoles for the treatment of CNS disorders
  申请人：Rogers N. Bruce

  公开号：US20060166974A1

  公开（公告）日：2006-07-27

  The present invention relates to α7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) such as cognitive deficits in schizophrenia, by administering to a mammal an α7 nicotinic receptor agonist of formula I as shown herein.

  本发明涉及如下式所述的α7烟碱受体激动剂，以及通过向哺乳动物施用本文所示的α7烟碱受体激动剂来治疗中枢神经系统（CNS）疾病，如精神分裂症中的认知缺陷的方法。
• Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
  申请人：Hurst S. Raymond

  公开号：US20060142349A1

  公开（公告）日：2006-06-29

  The present invention provides methods for identifying compounds useful in modulating α7 nicotinic acetylcholine receptors. The invention also provides compounds that prevent, suppress or inhibit desensitization of an α7 nicotinic acetylcholine receptor, and which resensitize such receptors. Pharmaceutical compositions, and methods of treatment, particularly in regard of neurological diseases are also described.

  本发明提供了鉴定有助于调节α7烟碱乙酰胆碱受体的化合物的方法。本发明还提供了防止、抑制或抑制α7烟碱乙酰胆碱受体脱敏以及使这种受体重新敏化的化合物。本发明还描述了药物组合物和治疗方法，特别是治疗神经系统疾病的方法。
• AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Pfizer Products Incorporated

  公开号：EP1814887A1

  公开（公告）日：2007-08-08
• METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR
  申请人：Pfizer Products Inc.

  公开号：EP1831683A1

  公开（公告）日：2007-09-12
• [EN] AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] AZABENZOXAZOLES POUR LE TRAITEMENT DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：PFIZER PROD INC

  公开号：WO2006051407A1

  公开（公告）日：2006-05-18

  [EN] The present invention relates to a7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an a7 nicotinic receptor agonist of formula I as shown herein. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant a7 nicotinic receptor agonist of formula I.
  [FR] Cette invention concerne des agonistes du récepteur a7-nicotinique représentés par la formule (I), tels que décrits dans les pièces descriptives de la demande, ainsi qu'un procédé pour traiter les troubles du système nerveux central et d'autres troubles chez un mammifère, notamment l'homme, en administrant à ce mammifère un agoniste du récepteur a7-nicotinique de formule (I). Cette invention concerne également des compositions pharmaceutiques contenant un véhicule pharmaceutiquement acceptable et un agoniste du récepteur a7-nicotinique de formule (I), pénétrant dans le système nerveux central .